Oral PCSK-9 inhibitor shows promise in early trial

In a phase 2b RCT involving 381 adults with a wide range of ASCVD risk, the investigational oral PCSK9 inhibitor MK-0616 resulted in significant dose-dependent LDL-C reductions of up to 61% at week 8. The drug was well tolerated during 8 weeks of treatment and a further 8 weeks of follow up.